Valuation: Control Bionics Limited

Market Cap 30.49M 21.25M 18.69M 17.36M 15.97M 29.95M 2.06B 208M 80.99M 1B 79.78M 78.06M 3.48B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.09M 18.55M 17.23M 15.85M 29.72M 2.04B 206M 80.36M 996M 79.16M 77.45M 3.46B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
54.68%
Yield 2024 *
-
Yield 2025 -
1 day-8.57%
1 week-13.51%
Current month-13.51%
1 month-28.89%
3 months+6.67%
6 months-5.88%
Current year+4.92%
1 week 0.06
Extreme 0.064
0.07
1 month 0.06
Extreme 0.064
0.09
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 01/12/2025
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-13.51%+60.00%-28.89% 21.81M
+0.23%-10.20%+15.82%-38.18% 15.8B
+9.95%+3.06%+10.99%+115.26% 1.63B
-1.17%-9.62%-38.03%-81.33% 1.14B
-4.66%-4.60%-37.93%+12.86% 1.01B
+0.57%-4.41%-30.13%-53.93% 627M
+2.48%-7.99%-46.66%-56.93% 505M
-0.47%-1.86%+37.32%-54.38% 449M
-2.94%-6.60%-56.72%-62.12% 372M
-2.25%+1.76%-21.82%-39.70% 350M
Average -0.74%-1.63%-10.72%-28.73% 2.19B
Weighted average by Cap. +0.61%-7.21%+6.08%-28.31%

Financials

2024 2025
Net sales 5.35M 3.73M 3.28M 3.05M 2.8M 5.26M 361M 36.44M 14.21M 176M 14M 13.7M 611M 6.14M 4.28M 3.77M 3.5M 3.22M 6.04M 415M 41.85M 16.32M 202M 16.08M 15.73M 702M
Net income -5.91M -4.12M -3.63M -3.37M -3.1M -5.81M -399M -40.28M -15.71M -195M -15.48M -15.14M -676M -6.11M -4.26M -3.75M -3.48M -3.2M -6M -412M -41.61M -16.23M -201M -15.99M -15.64M -698M
Net Debt -96.95K -67.58K -59.44K -55.22K -50.78K -95.24K -6.54M -660K -258K -3.19M -254K -248K -11.07M -237K -165K -145K -135K -124K -233K -16.02M -1.62M -630K -7.81M -621K -607K -27.1M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
23/07/26 A$0.0640 -8.57% 238,405
22/07/26 A$0.0700 +6.06% 19,245
21/07/26 A$0.0660 -2.94% 544,067
20/07/26 A$0.0680 -1.45% 221,044
17/07/26 A$0.0690 -1.43% 1,674,808

Annual profits - Rate of surprise